Becker's Healthcare February 16, 2024
Paige Twenter

A week ahead of schedule, the FDA approved the nation’s first cell therapy for advanced melanoma on Feb. 16.

The drug, Iovance Biotherapeutics’ Amtagvi, is a tumor-derived autologous T cell immunotherapy that expands a patient’s own T cells to fight the cancer.

The medicine is indicated for unresectable or metastatic melanoma, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More

Share This Article